Sugi Predict

Sugi Predict / Compounds / SCHEMBL2645976

SCHEMBL2645976

SCHEMBL2645976

CS(=O)(=O)c1ccc(Cl)cn1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NFE2L2 Q16236 5/20 0.41
▸ PTK2 Q05397 1/20 0.40
▸ PTGS1 P23219 1/20 0.40
▸ PTGS2 P35354 1/20 0.40
▸ POLB P06746 1/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ GPR119 Q8TDV5 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ FAAH O00519 1/20 0.39
▸ CCR9 P51686 1/20 0.39
▸ PIK3CD O00329 1/20 0.39
▸ PIP5K1C O60331 1/20 0.39
▸ PIK3CB P42338 1/20 0.39
▸ PI4KA P42356 1/20 0.39
▸ PIK3CG P48736 1/20 0.39
▸ PI4KB Q9UBF8 1/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ GRM4 Q14833 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pivalate SCHEMBL27460718 0.86 CCR9 (0.43) PTK2PTGS2POLBMEN1KMT2A
SCHEMBL30727325 0.83 NFE2L2 (0.39) NFE2L2PTK2PTGS1PTGS2POLB
SCHEMBL27326807 0.83 NFE2L2 (0.39) NFE2L2PTK2PTGS1PTGS2POLB
SCHEMBL1465207 0.80 NFE2L2 (0.42) NFE2L2PTK2POLBKDM4EMEN1
SCHEMBL1657082 0.79 KDM4E (0.41) NFE2L2PTK2POLBKDM4EMEN1
SCHEMBL3387459 0.78 L3MBTL1 (0.42) NFE2L2PTK2POLBKDM4EL3MBTL1
SCHEMBL2704697 0.78 CA1 (0.61) NFE2L2POLBKDM4EL3MBTL1
SCHEMBL2646778 0.78 POLB (0.41) NFE2L2PTK2POLBKDM4EMEN1
SCHEMBL427939 0.78 CA12 (0.52) PTK2POLBKDM4EMEN1KMT2A
SCHEMBL26107943 0.77 PI4KB (0.55) PTGS2GPR119FAAHPIK3CDPIP5K1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3704094-B1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2026-03-11 — — EP disclosed
US-20250122188-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2025-04-17 — — US disclosed
US-20240166652-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2024-05-23 — — US disclosed
EP-4356971-A2 MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2024-04-24 — — EP disclosed
CN-115947681-A Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2023-04-11 — — CN disclosed
US-20220363678-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY CALICO LIFE SCIENCES LLC (US) 2022-11-17 — — US disclosed
CN-109641844-B Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2022-11-01 — — CN disclosed
CN-112189008-A Modulators of integrated stress pathways 卡里科生命科学有限责任公司 2021-01-05 — — CN disclosed
US-20200361941-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ABBVIE INC. 2020-11-19 — — US disclosed
EP-3704094-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY Calico Life Sciences LLC (US) 2020-09-09 — — EP disclosed
US-20130225587-A1 COMPOUND FOR INCREASING KINASE ACTIVE AND APPLICATION THEREOF ZHEJIANG BETA PHARMA INCORPORATION (CN) 2013-08-29 — — US disclosed
US-20130225587-A1 COMPOUND FOR INCREASING KINASE ACTIVE AND APPLICATION THEREOF ZHEJIANG BETA PHARMA INCORPORATION (CN) 2013-08-29 — — US disclosed
EP-1702919-B1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE MSD KK (JP) 2012-05-30 — — EP disclosed
WO-2012062210-A1 COMPOUND FOR INCREASING KINASE ACTIVE AND APPLICATION THEREOF ZHEJIANG BETA PHARMA INC. (CN) 2012-05-18 — — WO disclosed
WO-2012062210-A1 COMPOUND FOR INCREASING KINASE ACTIVE AND APPLICATION THEREOF ZHEJIANG BETA PHARMA INC. (CN) 2012-05-18 — — WO disclosed
WO-2011094209-A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATONS MERCK SHARP & DOHME CORP. (US) 2011-08-04 — — WO disclosed
US-7728025-B2 2-heteroaryl-substituted benzimidazole derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-06-01 — — US disclosed
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative MSD K.K. (JP) 2008-03-20 — — US disclosed
CN-1926127-A Novel 2-heteroaryl substituted benzimidazole derivatives BANYU PHARMA CO LTD (JP) 2007-03-07 — — CN disclosed
EP-1702919-A1 NOVEL 2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-09-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225587-A1 COMPOUND FOR INCREASING KINASE ACTIVE AND APPLICATION THEREOF MAP3K7, MAP3K1, MAP3K6 NFE2L2 714/4885PTK2 209/4885PTGS1 660/4885
US-20200361941-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 NFE2L2 17/4885PTK2 1357/4885PTGS1 321/4885
US-20250122188-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 NFE2L2 17/4885PTK2 1357/4885PTGS1 321/4885
US-20240166652-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 NFE2L2 17/4885PTK2 1357/4885PTGS1 321/4885
US-20220363678-A1 MODULATORS OF THE INTEGRATED STRESS PATHWAY ATF4, ATF1, DDIT3 NFE2L2 17/4885PTK2 1357/4885PTGS1 321/4885
US-20080070928-A1 Novel 2-Heteroaryl-Substituted Benzimidazole Derivative GCK, GCKR, HK1 NFE2L2 216/4885PTK2 2402/4885PTGS1 1885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.